BIOCRAFT GENERIC CEPHALEXIN ANTIDUMPING SUIT VERSUS LYPHOMED WILL BE HEARD BY ITC ON DEC. 7; COMMERCE ANNOUNCES INTENT TO INVESTIGATE PENDING ITC DECISION